Hypereosinophilic Syndrome, Erythroderma as Clinical Debut. Case Report and Literature Review

Main Article Content

Alondra S. Polanco Llanes
Christian Abinadi Salazar Quijano
Can Pérez Eric E
Arjona Bojorquez Rashid I
Luna Garcia Javier
García Catalán Grisell
Alonzo Burgos Marcos A

Abstract

Eosinophilia is a common finding in clinical practice, but when elevated values ​​of eosinophils are found, it constitutes a diagnostic challenge. Hypereosinophilic syndrome is a group of rare disorders defined by persistent blood hypereosinophilia >1.5 × 109/l and associated to organ damage that result in a wide variety of clinical manifestations: fatigue with nonspecific skin lesions, to endomyocardial fibrosis, neurological compromise and life-threatening evolution.


The prognosis of the disease is variable and depends on the variant and the availability of specific treatment. 1- 2


We present the clinical case of a patient with a history of B symptoms and the presence of persistent erythroderma. The patient underwent several complementary studies, including skin biopsy without presenting a definitive diagnosis. Laboratory with persistence of hypereosinophilia that guided us towards the diagnosis of Idiopathic Hypereosinophilic Syndrome.

Article Details

How to Cite
Polanco Llanes, A. S., Salazar Quijano, C. A., E, C. P. E. ., I, A. B. R. ., Javier, L. G., Grisell, G. C. ., & A, A. B. M. . (2022). Hypereosinophilic Syndrome, Erythroderma as Clinical Debut. Case Report and Literature Review. International Journal of Medical Science and Clinical Research Studies, 2(07), 650–653. https://doi.org/10.47191/ijmscrs/v2-i7-10
Section
Articles

References

I. Grzegorz Helbig; Amy D. Klion; (2021). Hypereosinophilic syndromes – An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. Blood Reviews, (), –. doi:10.1016/j.blre.2021.100809

II. Liliana María Tamayo-Quijano, Lina María Aguirre-Hernández. (2018-06-09). Recurrent erythroderma leading to the diagnosis of hypereosinophilic syndrome. Allergy Mexico, 65, supplement 1.

III. Leru, PM Eosinophilic disorders: evaluation of the current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy 9, 36 (2019).https://doi.org/10.1186/s13601-019-0277-4

IV. Gao, Su-jun MD, PhDa; Wei, Wei MD, PhDb; Chen, Jiang-tao MD a ; Tan, Ye-hui MD, PhD; Yu, Cheng-bao MDd ; Litzow, Mark Robert MDc ; Liu, Qiu-ju MD, PhD a,c,* Hypereosinophilic Syndrome Presenting With Multiorgan Infiltration and Deep Vein Thrombosis, Medicine: August 2016 - Volume 95 - Number 35 - p e4658 doi: 10.1097/MD.0000000000004658

V. Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related conditions. J Allergy Clin Immunol 2012;130:607–12.

VI. Klion AD. How I treat hypereosinophilic syndromes. Blood 2015;126:1069–77.

VII. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;124: 1319–25.

VIII. Legrand F, Renneville A, MacIntyre E, Mastrilli S, Ackermann F, Cayuela JM, et al. The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. New insights based on a survey of 44 cases. Medicine. 2013;92:e1–9.

IX. Lefevre G, Copin MC, Staumont-Salle D, Avenel-Audran M, Aubert H, Taieb H, et al. The lymphoid variant of hypereosinophilic syndrome. Study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine. 2014;93:255–66.

X. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009;124: 1319–25.

XI. Kovacs N, Benjamin K, Holland-Thomas N, Moshkovich O, Nelsen LM, Ortega H, et al. Symptom assessment in hypereosinophilic syndrome: toward development of a patient-reported tool. J Allergy Clin Immunol Pract 2020;May 15. https://doi. org/10.1016/j.jaip.2020.04.069. S2213-2198(20)30472-4. Online ahead of print.

XII. Arefi M, García JL, Briz MM, de Arriba F, Rodríguez JN, Martín-Núñez G, et al. Response to imatinib mesylate in patients with hypereosinophilic syndrome. Int J Hematol. 2012; 96:320–26.